A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more patients — and soon, at…
A noninvasive diagnostic test to help distinguish ovarian cancer from benign pelvic masses will be available this fall. GlycoKnow Ovarian received a proprietary laboratory…
The number of uterine cancer cases and related deaths — the disease’s incidence and mortality rates — in the U.S. are expected to substantially rise…
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian cancer has begun dosing participants…
The first patient has been dosed in a Phase 3 trial testing the investigational therapy BAT8006 in people with platinum-resistant ovarian cancer, according to the…
IMNN-001, Imunon’s experimental immunotherapy for advanced ovarian cancer, boosts the body’s natural immune response by increasing levels of immune signaling proteins that aid in…
A Phase 3 clinical trial of Enhertu, a therapy developed by Daiichi Sankyo and AstraZeneca, has begun dosing its first patient with…
Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in people with platinum-resistant ovarian cancer.
